2017. Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT). SKIN The Journal of Cutaneous Medicine. 1, 3.1 (Oct. 2017), s24. DOI:https://doi.org/10.25251/skin.1.supp.23.